Novel mitogen-activated protein kinase kinase inhibitors

Bibliography

• Weinberg RA. Oncogenes and tumor suppressor genes. CA Cancer J Clin 1994;44(3):160-70
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Cancer Statistics, 2009. CA Cancer J Clin 2009;59(4):225-49
   PubMed Web of Science ®Google Scholar
• Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009;283(2):125-34
   PubMed Web of Science ®Google Scholar
• Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49(17):4682-9
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54
   PubMed Web of Science ®Google Scholar
• Hoshino R, Chatani Y, Yamori T, Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18(3):813-22
   PubMed Web of Science ®Google Scholar
• Brose MS, Volpe P, Feldman M, BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62(23):6997-7000
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28(7):742-62
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Abrams SL, Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008;22(4):708-22
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M, EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101(36):13306-11
   PubMed Web of Science ®Google Scholar
• Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002;109(7):863-7
   PubMed Web of Science ®Google Scholar
• Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008;68(9):3077-80, discussion 80
   PubMed Web of Science ®Google Scholar
• Marks JL, Gong Y, Chitale D, Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 2008;68(14):5524-8
   PubMed Web of Science ®Google Scholar
• Emery CM, Vijayendran KG, Zipser MC, MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009;106(48):20411-16
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26(22):3291-310
   PubMed Web of Science ®Google Scholar
• Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4(12):937-47
   PubMed Web of Science ®Google Scholar
• Sharma A, Tran MA, Liang S, Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res 2006;66(16):8200-9
   PubMed Web of Science ®Google Scholar
• Collisson EA, De A, Suzuki H, Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res 2003;63(18):5669-73
   PubMed Web of Science ®Google Scholar
• Ohren JF, Chen H, Pavlovsky A, Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004;11(12):1192-7
   PubMed Web of Science ®Google Scholar
• Catalanotti F, Reyes G, Jesenberger V, A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat Struct Mol Biol 2009;16(3):294-303
   PubMed Web of Science ®Google Scholar
• Scholl FA, Dumesic PA, Barragan DI, Selective role for Mek1 but not Mek2 in the induction of epidermal neoplasia. Cancer Res 2009;69(9):3772-8
   PubMed Web of Science ®Google Scholar
• Skarpen E, Flinder LI, Rosseland CM, MEK1 and MEK2 regulate distinct functions by sorting ERK2 to different intracellular compartments. FASEB J 2008;22(2):466-76
   PubMed Web of Science ®Google Scholar
• Ussar S, Voss T. MEK1 and MEK2, different regulators of the G1/S transition. J Biol Chem 2004;279(42):43861-9
   PubMed Web of Science ®Google Scholar
• Sebolt-Leopold JS. MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr Pharm Des 2004;10(16):1907-14
   PubMed Web of Science ®Google Scholar
• Haystead TA, Dent P, Wu J, Ordered phosphorylation of p42mapk by MAP kinase kinase. FEBS Lett 1992;306(1):17-22
   PubMed Web of Science ®Google Scholar
• Wang JY, Wilcoxen KM, Nomoto K, Wu S. Recent advances of MEK inhibitors and their clinical progress. Curr Top Med Chem 2007;7(14):1364-78
   PubMed Web of Science ®Google Scholar
• Solit DB, Garraway LA, Pratilas CA, BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439(7074):358-62
   PubMed Web of Science ®Google Scholar
• Ramjaun AR, Downward J. Ras and phosphoinositide 3-kinase: partners in development and tumorigenesis. Cell Cycle 2007;6(23):2902-5
   PubMed Web of Science ®Google Scholar
• Wong KK. Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. Recent Pat Anticancer Drug Discov 2009;4(1):28-35
   PubMed Web of Science ®Google Scholar
• Thalhamer T, McGrath MA, Harnett MM. MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford) 2008;47(4):409-14
   PubMed Web of Science ®Google Scholar
• Weissmann G. The pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2006;64(1-2):12-5
   PubMedGoogle Scholar
• Favata MF, Horiuchi KY, Manos EJ, Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273(29):18623-32
   PubMed Web of Science ®Google Scholar
• Sebolt-Leopold JS, Dudley DT, Herrera R, Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999;5(7):810-16
   PubMed Web of Science ®Google Scholar
• Barrett SD, Bridges AJ, Dudley DT, The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett 2008;18(24):6501-4
   PubMed Web of Science ®Google Scholar
• Lorusso PM, Adjei AA, Varterasian M, Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005;23(23):5281-93
   PubMed Web of Science ®Google Scholar
• Rinehart J, Adjei AA, Lorusso PM, Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004;22(22):4456-62
   PubMed Web of Science ®Google Scholar
• Haura EB, Ricart AD, Larson TG, A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2010;16(8):2450-7
   PubMed Web of Science ®Google Scholar
• Yeh TC, Marsh V, Bernat BA, Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007;13(5):1576-83
   PubMed Web of Science ®Google Scholar
• Adjei AA, Cohen RB, Franklin W, Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26(13):2139-46
   PubMed Web of Science ®Google Scholar
• Hersey P, Bastholt L, Chiarion-Sileni V, Small molecules and targeted therapies in distant metastatic disease. Ann Oncol 2009;20(Suppl 6):vi35-40
   PubMed Web of Science ®Google Scholar
• Iverson C, Larson G, Lai C, RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res 2009;69(17):6839-47
   PubMed Web of Science ®Google Scholar
• McDermott U, Sharma SV, Dowell L, Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA 2007;104(50):19936-41
   PubMed Web of Science ®Google Scholar
• Flaherty KT. Sorafenib: delivering a targeted drug to the right targets. Expert Rev Anticancer Ther 2007;7(5):617-26
   PubMed Web of Science ®Google Scholar
• Goto M, Chow J, Muramoto K, E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8, 9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradec ine-1,7(8H)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1: in vitro characterization of its anti-inflammatory and antihyperproliferative activities. J Pharmacol Exp Ther 2009;331(2):485-95
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Nagahara T, Okano J, Murawaki Y. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. Oncol Rep 2008;20(4):863-72
   PubMed Web of Science ®Google Scholar
• Holcomb B, Yip-Schneider MT, Matos JM, Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies. J Gastrointest Surg 2008;12(2):288-96
   PubMed Web of Science ®Google Scholar
• Haass NK, Sproesser K, Nguyen TK, The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008;14(1):230-9
   PubMed Web of Science ®Google Scholar
• Davies BR, Logie A, McKay JS, AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007;6(8):2209-19
   PubMed Web of Science ®Google Scholar
• Katayama K, Yoshioka S, Tsukahara S, Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther 2007;6(7):2092-102
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363(9):809-19
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou G, Song K, Yen I, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464(7287):431-5
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q, Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468(7326):902-3
   Google Scholar
• Corcoran RB, Dias-Santagata D, Bergethon K, BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 2010;3(149):ra84
   PubMed Web of Science ®Google Scholar
• Yip-Schneider MT, Klein PJ, Wentz SC, Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. J Pharmacol Exp Ther 2009;329(3):1063-70
   PubMed Web of Science ®Google Scholar
• Legrier ME, Yang CP, Yan HG, Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res 2007;67(23):11300-8
   PubMed Web of Science ®Google Scholar
• Chang Q, Chapman MS, Miner JN, Hedley DW. Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts. BMC Cancer 2010;10:515
   PubMed Web of Science ®Google Scholar
• Hoeflich KP, O'Brien C, Boyd Z, In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009;15(14):4649-64
   PubMed Web of Science ®Google Scholar
• Mirzoeva OK, Das D, Heiser LM, Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009;69(2):565-72
   PubMed Web of Science ®Google Scholar
• O'Brien C, Wallin JJ, Sampath D, Predictive biomarkers of sensitivity to the phosphatidylinositol 3′ kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010;16(14):3670-83
   PubMed Web of Science ®Google Scholar
• Turke AB, Engelman JA. PIKing the right patient. Clin Cancer Res 2010;16(14):3523-5
   PubMed Web of Science ®Google Scholar